middle.news
Imugene Advances Cancer Trials, Secures $46M Funding Boost
8:50am on Friday 31st of January, 2025 AEDT
•
Healthcare
Read Story
Imugene Advances Cancer Trials, Secures $46M Funding Boost
8:50am on Friday 31st of January, 2025 AEDT
Key Points
Bile tract cancer patient maintains complete response over two years in MAST trial
First patient dosed in intratumoural arm of onCARlytics Phase 1 trial
Australian site opens for azer-cel Phase 1b trial with initial patient enrolment
Convertible notes and warrants raise $20 million upfront, potential $46 million total
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE